MARKET

ANAB

ANAB

AnaptysBio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

22.54
-0.53
-2.30%
Closed 16:41 07/02 EDT
OPEN
23.71
PREV CLOSE
23.07
HIGH
23.71
LOW
22.41
VOLUME
182.18K
TURNOVER
--
52 WEEK HIGH
56.72
52 WEEK LOW
10.00
MARKET CAP
614.83M
P/E (TTM)
-7.3125
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 9 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ANAB stock price target is 18.57 with a high estimate of 28.00 and a low estimate of 16.00.

EPS

ANAB News

More
Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Contact the Firm; Should Management be Held Accountable for Investors' Losses?
PR Newswire · 3d ago
AnaptysBio, Inc. (ANAB) Upgraded to Buy: What Does It Mean for the Stock?
Zacks · 06/22 17:00
Hedge Funds Are Done Buying AnaptysBio, Inc. (ANAB)
Insider Monkey · 06/15 13:59
Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?
Is (ANAB) Outperforming Other Medical Stocks This Year?
Zacks · 06/10 15:30
Here's Why AnaptysBio Rose 22.1% in May
The beaten-up biopharma stock trekked higher after the development-stage company delivered a slew of pipeline updates alongside first quarter 2020 operating results. The small-cap stock has now gained 28% since the beginning of 2020, although shares of Anapty
Motley Fool · 06/09 22:09
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AnaptysBio, Inc. - ANAB
Pomerantz LLP is investigating claims on behalf of investors AnaptysBio, Inc. (“AnaptysBio” or the “Company”) (ANAB). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns wheth
GlobeNewswire · 05/27 11:33
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of FITB, I, MESA and ZM
GlobeNewswire · 05/27 03:50
ANAPTYSBIO 24 HOUR DEADLINE ALERT: FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Deadline in Class Action Lawsuit Against AnaptysBio, Inc. - ANAB
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until May 26, 2020 to file lead plaintiff applications in a securities class action lawsuit against AnaptysBio,
PR Newswire · 05/26 02:50

Industry

Biotechnology & Medical Research
+0.68%
Pharmaceuticals & Medical Research
+0.61%

Hot Stocks

Symbol
Price
%Change

About ANAB

AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product pipeline includes ANB020 and ANB019, which are being developed to treat severe inflammatory disorders with unmet medical need. The Company's ANB020 product candidate is an antibody that inhibits the activity of interleukin-33, and is used for the treatment of severe adult asthma and severe adult peanut allergy. In addition, the Company is engaged in developing its ANB019 product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases called generalized pustular psoriasis (GPP) and palmoplantar pustular psoriasis (PPP).
More

Webull offers kinds of AnaptysBio Inc stock information, including NASDAQ:ANAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANAB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ANAB stock methods without spending real money on the virtual paper trading platform.